SCHEMBL4736985

SCHEMBL4736985

CCOC(=O)CNC(=O)c1c(O)nc(-c2cccc(Br)c2)n(Cc2ccccc2)c1=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN3 Q9H6Z9 2/20 0.50
GLA P06280 1/20 0.44
HPGD P15428 2/20 0.43
LMNA P02545 2/20 0.43
ALDH1A1 P00352 3/20 0.43
KDM4E B2RXH2 2/20 0.43
HSD17B10 Q99714 2/20 0.42
MEN1 O00255 1/20 0.42
USP2 O75604 1/20 0.42
TP53 P04637 1/20 0.42
MAPT P10636 1/20 0.42
ALOX15 P16050 1/20 0.42
MAPK1 P28482 1/20 0.42
HTT P42858 1/20 0.42
KMT2A Q03164 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
CFTR P13569 1/20 0.42
EGLN1 Q9GZT9 4/20 0.42
CYP19A1 P11511 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4992207 0.91 EGLN3 (0.54) EGLN3HPGDLMNAALDH1A1KDM4E
SCHEMBL4995854 0.89 EGLN3 (0.57) EGLN3CFTREGLN1
SCHEMBL4988756 0.88 EGLN3 (0.56) EGLN3CFTREGLN1
SCHEMBL4988752 0.86 EGLN3 (0.48) EGLN3LMNAALDH1A1TP53MAPT
SCHEMBL4995930 0.84 EGLN3 (0.65) EGLN3HPGDLMNAALDH1A1HSD17B10
SCHEMBL4991419 0.84 EGLN3 (0.49) EGLN3GLAHPGDALDH1A1KDM4E
SCHEMBL4737644 0.81 EGLN3 (0.47) EGLN3HPGDLMNAALDH1A1KDM4E
SCHEMBL4996305 0.80 EGLN3 (0.59) EGLN3EGLN1
SCHEMBL4992677 0.80 EGLN3 (0.48) EGLN3HPGDLMNAALDH1A1KDM4E
SCHEMBL4992247 0.79 EGLN3 (0.62) EGLN3LMNAALDH1A1SMN1; SMN2EGLN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008089051-A1 N-SUBSTITUTED GLYCINE DERIVATIVES: PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2008-07-24 WO disclosed
US-20080171756-A1 N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2008-07-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080171756-A1 N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors HIF1AN, EGLN2, EGLN3 EGLN3 3/4885GLA 1615/4885HPGD 30/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.